Creative Biolabs provides comprehensive genomic alteration assessment services targeting cell cycle dysregulation. We utilize NGS and multi-omics to pinpoint vulnerabilities in CDK/cyclin complexes and checkpoints, delivering actionable insights for precision oncology.
Learn More →Small Molecule Drug Discovery Services
Creative Biolabs provides a robust, end-to-end solution for drug developers aiming to navigate the increasingly complex chemical landscape. Our deliverables go beyond simple "hits"; we provide deeply characterized lead compounds optimized for potency, selectivity, and safety. By integrating AI-assisted virtual screening with high-resolution structural biology, we solve the critical problem of high attrition in early-stage research and development. Our multidisciplinary team assists your project by identifying novel binding sites, improving the solubility of recalcitrant scaffolds, and ensuring that your leads possess the necessary pharmacokinetic profile for success.
Background Featured Services What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Scientific Context and Evolution of Modern Small-Molecule Modalities
Small molecules continue to represent the foundational pillar of global pharmacotherapy, accounting for approximately 90% of all approved drugs due to their unparalleled oral bioavailability, tissue distribution, and ease of manufacturing. However, as traditional targets like kinases and G protein-coupled receptors (GPCRs) become saturated, the field is undergoing a paradigm shift toward "undruggable" territories. Modern discovery now emphasizes the modulation of RNA architectures and protein-protein interactions (PPIs), which were once considered chemically inaccessible. By leveraging revolutionary tools like DNA-encoded libraries (DEL) and deep learning architectures such as molecular transformers, Creative Biolabs is overcoming the historical challenges associated with biological target flexibility and the astronomical vastness of chemical space.
Integrated Precision Engineering Solution
End-to-End Small Molecule Immunotherapy Development
Technical Offerings in Small-Molecule Discovery
Our service suite is engineered to address the most significant hurdles in modern medicinal chemistry, particularly for challenging targets such as PPIs and structured RNA.
Next-Generation Hit Discovery
We offer a diversified toolbox beyond traditional high-throughput screening (HTS). This includes DEL for screening billions of molecules, fragment-based drug discovery (FBDD) for mapping "hotspots," and affinity selection-mass spectrometry (AS-MS) for label-free binding assays.
Generative De Novo Design
Utilizing variational autoencoders (VAEs) and generative adversarial networks (GANs), Creative Biolabs designs novel chemical entities with high validity and uniqueness, moving beyond the limitations of existing chemical catalogs.
RNA-Targeted Discovery Platforms
As the industry shifts toward the vast portion of the genome transcribed into RNA, we provide specialized screening for mRNA, lncRNA, and miRNAs using ensemble-based docking and molecular dynamics (MD) simulations.
AI-Enhanced Lead Optimization
Our deep learning architectures, including molecular transformers and graph neural networks, predict structure-activity relationships (SAR) with high precision, allowing for fewer synthetic cycles and faster optimization.
Partner with Our Scientists to Identify Your Next High-Affinity Lead – Request a Detailed Technical Feasibility Assessment
Workflow
Creative Biolabs maintains a transparent and rigorous workflow designed to mitigate risk and ensure high-quality data outputs at every milestone.
Publication
This review provides an accessible introduction to small-molecule drug discovery, from target validation to preclinical development. The authors outline key stages, screening, lead optimization, and safety assessment, highlighting the iterative design-make-test-analyze cycle and the critical role of DMPK studies. They also discuss emerging technologies such as artificial intelligence and novel modalities that expand druggable space. Despite the high cost and attrition, small molecules remain a dominant and evolving therapeutic class, offering flexibility and broad disease coverage.
Fig.1 The drug discovery pipeline: from target identification to market approval. 1
Why Choose Us?
Creative Biolabs stands at the critical intersection of traditional medicinal chemistry and high-throughput digital innovation. Our platform is specifically engineered to maximize the hit rate in early discovery by directly addressing the modern trend of declining research and development efficiency. We offer a unique, proprietary portfolio of RNA-targeted discovery tools and ultra-large virtual libraries, containing trillions of synthesizable molecules, that standard providers simply cannot navigate. Our commitment to data-driven accuracy is best demonstrated by our predictive ADMET models, where properties such as hERG cardiotoxicity and blood-brain barrier permeability are calculated with industry-leading statistical confidence.
Experience the Creative Biolabs Competitive Edge – Connect with Us Today for a Personalized Service Quote
FAQs
How do you handle "undruggable" targets like PPIs?
We utilize a combination of FBDD to find small binding "hotspots" and generative AI to design molecules that can bridge large, flat interface surfaces with high affinity.
Can your platform target RNA specifically without a protein partner?
Yes, we have specialized platforms for mRNA and non-coding RNAs, utilizing ensemble docking against multiple conformers to account for the high dynamic flexibility of RNA structures in solution.
What is the primary benefit of DEL for my project?
DEL allows for the screening of billions of compounds in a single experiment. This significantly increases the probability of finding hits for novel or difficult targets that are not represented in standard HTS libraries.
Customer Review
-
Enhanced Molecular Selectivity and Target Specificity
Using Creative Biolabs' FBDD platform in our research has significantly facilitated the discovery of selective inhibitors for a shallow-pocket protein. The fragment-growing strategy was precise and heavily supported by structural evidence. - Dr. Alan Sc** -
Breakthrough Insights into Dynamic RNA Targeting
The RNA-targeted discovery services provided a novel starting point for our lncRNA project. Their MD simulations revealed hidden pockets that traditional docking missed, allowing us to stabilize a specific transcript conformation. - Prof. Li* Wa*
Related Services
Targeted Protein Degradation Service
Creative Biolabs provides targeted protein degradation services, leveraging the ubiquitin-proteasome system to resolve undruggable targets. We quantify ternary complex formation and E3 ligase recruitment to evaluate degradation potency and SAR-driven lead optimization.
Learn More →Chemokine Production Measurement Service
Creative Biolabs provides a comprehensive chemokine production measurement service, quantifying CC, CXC, CX3CL, and XC subfamilies. Utilizing ELISA and flow cytometry, we analyze tumor microenvironment immune recruitment to validate immunotherapy targets.
Learn More →How to Contact Creative Biolabs
Creative Biolabs offers a technologically superior ecosystem for small-molecule discovery, blending AI innovation with deep biological expertise to solve the industry's toughest challenges. From targeting dynamic RNA architectures to navigating "undruggable" protein interfaces, our platform is built to deliver high-quality leads that stand up to rigorous scrutiny.
Transform Your Therapeutic Vision into a Validated Lead – Contact Our Team to Initiate Your Discovery Campaign
Reference
- Southey, Michelle WY, and Michael Brunavs. "Introduction to small molecule drug discovery and preclinical development." Frontiers in Drug Discovery 3 (2023): 1314077. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fddsv.2023.1314077
Download our brochureLoading case studies...
Online Inquiry